RNS Number : 0456H
Haleon PLC
04 October 2024
 

Icon Description automatically generated

4 October 2024

HALEON PLC 

("Haleon" or "the Company")  

 

TR-1: Standard form for notification of major holdings

1. Issuer Details

ISIN

GB00BMX86B70

Issuer Name

HALEON PLC

UK or Non-UK Issuer

UK

2. Reason for Notification

An acquisition or disposal of voting rights

3. Details of person subject to the notification obligation

Name

Pfizer Inc.

City of registered office (if applicable)

New York

Country of registered office (if applicable)

United States of America

4. Details of the shareholder

Name

City of registered office

Country of registered office

State Street Nominees Limited

London

United Kingdom

Guaranty Nominees Limited

London

United Kingdom

5. Date on which the threshold was crossed or reached

03-Oct-2024

6. Date on which Issuer notified

03-Oct-2024

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8.A)

% of voting rights through financial instruments (total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights held in issuer

Resulting situation on the date on which threshold was crossed or reached

15.040000

0.000000

15.040000

1361709764

Position of previous notification (if applicable)

22.580000

0.000000

22.580000


8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

8A. Voting rights attached to shares

Class/Type of shares ISIN code(if possible)

Number of direct voting rights (DTR5.1)

Number of indirect voting rights (DTR5.2.1)

% of direct voting rights (DTR5.1)

% of indirect voting rights (DTR5.2.1)

Ordinary Shares GB00BMX86B70


967251860


10.680000

Restricted ADSs


394457904


4.360000

Sub Total 8.A

1361709764

15.040000%

8B1. Financial Instruments according to (DTR5.3.1R.(1) (a))

Type of financial instrument

Expiration date

Exercise/conversion period

Number of voting rights that may be acquired if the instrument is exercised/converted

% of voting rights

 





Sub Total 8.B1




8B2. Financial Instruments with similar economic effect according to (DTR5.3.1R.(1) (b))

Type of financial instrument

Expiration date

Exercise/conversion period

Physical or cash settlement

Number of voting rights

% of voting rights

 






Sub Total 8.B2




9. Information in relation to the person subject to the notification obligation

1. Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer.

Ultimate controlling person

Name of controlled undertaking

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

 





10. In case of proxy voting

Name of the proxy holder

 

The number and % of voting rights held

 

The date until which the voting rights will be held

 

11. Additional Information

This notification relates to the sale by Pfizer Inc. ("Pfizer") of a portion of its interest in Haleon plc ("Haleon").
Pfizer sold 640,000,000 Haleon ordinary shares ("Ordinary Shares") pursuant to a secondary offering announced on 30 September 2024. In connection with the offering, and in addition to the 640,000,000 Ordinary Shares in the offering, Pfizer sold 60,526,315 Ordinary Shares to Haleon in an off-market sale in accordance with the terms of a share purchase deed between Haleon and Pfizer that was previously approved by Haleon's shareholders.
These calculations are based on Haleon's issued voting share capital of 9,053,360,882 ordinary shares with voting rights, as communicated by Haleon in their announcement on total voting rights and capital dated 3 October 2024.

Pfizer holds its ordinary shares in Haleon through (i) State Street Nominees Limited, and (ii) Guaranty Nominees Limited (in respect of its American depositary shares representing Ordinary Shares), which hold the legal title to those shares on Pfizer's behalf.

12. Date of Completion

03-Oct-2024

13. Place Of Completion

New York                                                                                               

 

         

Amanda Mellor, Company Secretary

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
HOLUSVURSBURRAA
Haleon (LSE:HLN)
過去 株価チャート
から 9 2024 まで 10 2024 Haleonのチャートをもっと見るにはこちらをクリック
Haleon (LSE:HLN)
過去 株価チャート
から 10 2023 まで 10 2024 Haleonのチャートをもっと見るにはこちらをクリック